Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 3 » Issue 1

Mechanisms of atherothrombosis in chronic obstructive pulmonary disease

Authors Fimognari FL, Scarlata S, Conte ME, Incalzi RA

Published 7 March 2008 Volume 2008:3(1) Pages 89—96

DOI https://doi.org/10.2147/COPD.S1401



Filippo Luca Fimognari1,2, Simone Scarlata1, Maria Elisabetta Conte1, Raffaele Antonelli Incalzi1

1Health Centre for Elderly, Chair of Geriatrics, University Campus Bio Medico, Rome, Italy; 2Internal Medicine; ASL Roma G, Leopoldo Parodi-Delfino Hospital; Colleferro, Rome, Italy

Abstract: Patients affected by chronic obstructive pulmonary disease (COPD) have an increased risk of atherothrombotic acute events, independent of smoking and other cardiovascular risk factors. As a consequence, myocardial ischemia is a relevant cause of death in these patients. We reviewed studies concerning the potential mechanisms of atherothrombosis in COPD. Bronchial inflammation spreads to the systemic circulation and is known to play a key role in plaque formation and rupture. In fact, C-reactive protein blood levels increase in COPD and provide independent prognostic information. Systemic inflammation is the first cause of the hypercoagulable state commonly observed in COPD. Furthermore, hypoxia is supposed to activate platelets, thus accounting for the increased urinary excretion of platelet-derived thromboxane in COPD. The potential metabolic risk in COPD is still debated, in that recent studies do not support an association between COPD and diabetes mellitus. Finally, oxidative stress contributes to the pathogenesis of COPD and may promote oxidation of low-density-lipoproteins with foam cells formation. Retrospective observations suggest that inhaled corticosteroids may reduce atherothrombotic mortality by attenuating systemic inflammation, but this benefit needs confirmation in ongoing randomized controlled trials. Physicians approaching COPD patients should always be aware of the systemic vascular implications of this disease.

Keywords: COPD, atherothrombosis, cardiovascular risk, mortality

Creative Commons License © 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.